-
The potential upside from Avila's small molecule platform is reflected in the deal terms from Celgene, which also will be gaining a Phase I program for B cell malignancies to complement Revlimid.
Published on 1/30/2012
-
Amgen finally talked Micromet into selling the company, but first they needed six months to test the waters with a discovery and development deal for Micromet's BiTE technology.
Published on 1/30/2012
-
With its bid for Illumina, Roche is betting its IVD framework and hospital customer base will give it a leg up in accessing the biggest potential growth area in MDx: whole genome sequencing.
Published on 1/30/2012
-
Roche re-sequences Roche-Illumina portfolio The acquisition of Illumina Inc. (NASDAQ:ILMN) would broaden and complement Roche's menu of genomics technologies for research and diagnostics customers. While Roche (SIX:…
Published on 1/30/2012
-
AstraZeneca's grassroots BD effort in Asia has yielded a preclinical TKI for cancer from Hutchison, and validated the 10 years and almost $100 million the biotech spent building in-house discovery.
Published on 1/23/2012
-
Epigenetics land grab Epigenetics landscape Large companies have been stepping up deal activity in the epigenetics space over the last three years. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has disclosed the most …
Published on 1/23/2012
-
Genentech has joined the race into epigenetics, concluding that Constellation is best positioned to both validate the ever-increasing number of epigenetic targets and to identify small molecules to modulate them.
Published on 1/23/2012
-
Inhibitex's decision to swap antibacterials for antivirals transformed the company from an invisible penny stock into a $2.5 billion takeout as Bristol-Myers looks to compete in the all-oral HCV cocktail arena.
Published on 1/16/2012
-
As Teva's new CEO, Jeremy Levin's job will be to restore investor confidence in management. But he also will be aiming to dispel notions that the company's growth story will be all about branded drugs.
Published on 1/16/2012
-
Karo Bio thinks its deal with Pfizer validates the biotech's nuclear receptor programs, and changes the perception that the company has nothing of value but eprotirome.
Published on 1/16/2012
-
Rebooting confidence Confidence wanes Shlomo Yanai, outgoing CEO of Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), led the company through a period of rapid growth in sales and profitability as measured by EPS …
Published on 1/16/2012
-
Rebooting confidence Teva diversifies Since Shlomo Yanai became president and CEO in March 2007, Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) has been reconfigured from a company in which generics and the U.S. …
Published on 1/16/2012
-
A two-step deal process will soon unite Intarcia and CRO Quintiles with one of two potential pharma partners, which could provide the biotech's once-yearly exenatide a faster path to market in diabetes.
Published on 1/9/2012
-
Alexion will have to wait three years to find out if its purchase of Enobia for $610 million up front will provide a Soliris-like winner in ultra-Orphan metabolic bone diseases.
Published on 1/2/2012
-
Amgen says it could have built a biosimilars business on its own, but decided partnering with Watson would be better for shareholders as well as provide acumen in generics.
Published on 1/2/2012
-
Takeda decided it is now too late to play in the ESA space in Japan, and will instead focus on launching Affymax's peginesatide in the U.S. and Europe.
Published on 1/2/2012
-
Abbott nearly doubled its investment in Reata's AIM portfolio, paying $400M to lock up hundreds of next-generation compounds with the same MOA as bardoxolone methyl but more versatile pharmacological properties.
Published on 12/19/2011
-
Samsung is a newcomer to biotherapeutics, but the Korean conglomerate's track record in entering new businesses through joint ventures made it the ideal partner for Biogen Idec's one play in biosimilars.
Published on 12/19/2011
-
J&J says the science and first-mover advantage behind Pharmacyclics' Btk inhibitor were enough for the pharma to step outside its focus on the tumor microenvironment -- and to justify a $150M upfront payment.
Published on 12/12/2011
-
Gilead is betting it can recreate the success it has had with a nucleotide analog in HIV by making Pharmasset's PSI-7977 the tenofovir of the HCV space.
Published on 12/5/2011
-
Gilead's second-strike nuc Gilead's sales trajectory In 2010, Gilead Sciences Inc. (NASDAQ:GILD) reported sales of $6.3 billion from its HIV drugs, which accounted for 86% of total product sales. HIV drug sales have…
Published on 12/5/2011
-
Lundbeck psyched up Lundbeck's deals With three of its highest revenue products going off patent in 2012-14, Lundbeck has embarked on a deal strategy to broaden its product portfolio and increase its geographic …
Published on 12/5/2011
-
Lundbeck says its compound-pooling deal with Otsuka goes beyond replacing patent-related revenue losses, giving the Danish pharma products to establish a foothold in the U.S. psychiatry market.
Published on 12/5/2011
-
With partner Lilly gone, Amylin believes it can compete in diabetes with an enlarged sales force dedicated solely to its exenatide franchise, but the cash flow and profit story hinges on a January PDUFA date for …
Published on 11/14/2011
-
In its first significant deal since naming new heads of BD and R&D, Biogen Idec concluded Portola's PRT062607's Syk inhibitor program offers best-in-class potential among oral RA agents.
Published on 11/7/2011